Thomas D. Nolin, PharmD, PhD, FASN
Dr. Tom Nolin is Associate Dean for Research and Sponsored Programs in the University of Pittsburgh School of Pharmacy, and he is Director of the University’s Small Molecule Biomarker Core facility. Dr. Nolin has a strong record of interdisciplinary and interinstitutional collaborations with regulatory, pharmaceutical industry, and academic scientists in the conduct of a broad range of clinical-translational studies and policy initiatives related to kidney disease. His primary research focuses on developing an understanding of the impact of kidney disease and renal replacement therapy on nonrenal drug metabolism and transport pathways and corresponding effects on drug exposure and response. He has served as co-chair of the Kidney Health Initiative workgroup to assess pharmacokinetics during renal replacement therapy, as co-chair of the Extracorporeal Treatments in Poisoning Workgroup, as an invited participant in KDIGO international controversies conferences, and as an invited panelist on FDA advisory committees addressing nephropharmacology related topics. Dr. Nolin has published and presented extensively. He serves on the editorial board of the Clinical Journal of the American Society of Nephrology, and as an Editor of the textbook Pharmacotherapy: A Pathophysiologic Approach. He is a Fellow and Regent of the American College of Clinical Pharmacology, a Fellow of the American College of Clinical Pharmacy, and a Fellow of the American Society of Nephrology. Dr. Nolin holds a B.S. in Pharmacy from the University of Connecticut, a M.S. in Pharmacy from the University of North Carolina at Chapel Hill, and Pharm.D. and Ph.D. degrees from the University of Pittsburgh.